Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Grassley pushes universities for transparency

Executive Summary

Officials at academic research institutions are the latest group to feel pressure from Sen. Chuck Grassley, R-Iowa, who is looking to shed light on drug companies' financial ties to researchers. The ranking Republican on the Senate Finance Committee sent letters to leaders of almost two dozen universities asking them to examine their conflict of interest and financial disclosure policies. Grassley says he is concerned that drug company funding can influence scientific studies and that university faculty do not always report their outside income. Grassley previously prodded NIH director Elias Zerhouni to review his agency's oversight of outside grant recipients' conflicts of interest (1"The Pink Sheet," June 30, 2008, In Brief)

You may also be interested in...

NIH's Revised Conflict Of Interest Policy Will Close The Nemeroff Loophole, Collins Tells Congress

New attention to a simmering scandal has increased scrutiny of NIH's effort to tighten up its existing conflict of interest policy and on a loophole the agency must be sure to eliminate

Sunshine rules ensnare Emory department chair

Charles Nemeroff is stepping down as chairman of the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine because of failure to report outside income from drug companies. An investigation by Emory found that during 2000-2005, Nemeroff failed to report more than $800,000 in income from GSK for more than 250 speaking engagements. Nemeroff says he believed his presentations to be educational lectures not subject to the school's disclosure requirements. The investigation, which focused on the GSK payments because the firm was the largest single payer to Nemeroff, has found no evidence the payments affected his care for clinical trial participants or biased his research. Nevertheless, Nemeroff, who will continue to teach at Emory, will be subject to new restrictions on his outside activities. Sen. Chuck Grassley, R-Iowa, brought attention to Nemeroff's activities as part of his campaign to shed light on drug companies' financial ties to doctors and researchers (1"The Pink Sheet," Sept. 22, 2008, In Brief)

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts